scholarly journals Bilateral Ureteral Stenosis with Hydronephrosis as First Manifestation of Granulomatosis with Polyangiitis (Wegener’s Granulomatosis): A Case Report and Review of the Literature

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Joelle Suillot ◽  
Jürg Bollmann ◽  
Samuel Rotman ◽  
Eric Descombes

Ureteral stenosis is a rare manifestation of granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis). We report the case of a 76-year-old woman with progressive renal failure in which bilateral hydronephrosis due to ureteral stenosis was the first manifestation of the disease. Our patient also had renal involvement with pauci-immune crescentic glomerulonephritis associated with high titers of anti-proteinase 3 c-ANCAs, but no involvement of the upper or lower respiratory tract. The hydronephrosis and renal function rapidly improved under immunosuppressive therapy with high-dose corticosteroids and intravenous pulse cyclophosphamide. We reviewed the literature and found only ten other reported cases of granulomatosis with polyangiitis/Wegener’s granulomatosis and intrinsic ureteral stenosis: in two cases, the presenting clinical manifestation was unilateral hydronephrosis and in only two others was the hydronephrosis bilateral, but this complication developed during a relapse of the disease. This case emphasizes the importance of including ANCA-related vasculitis in the differential diagnosis of unusual cases of unilateral or bilateral ureteral stenosis.

2016 ◽  
Vol 2016 ◽  
pp. 1-3 ◽  
Author(s):  
Roy Ujjawal ◽  
Pan Koushik ◽  
Panwar Ajay ◽  
Chakrabarti Subrata

Wegener’s granulomatosis or granulomatosis with polyangiitis is a necrotizing vasculitis affecting both arterioles and venules. The disease is characterized by the classical triad involving acute inflammation of the upper and lower respiratory tracts with renal involvement. However, the disease pathology can affect any organ system. This case presents Wegener’s granulomatosis presenting with facial nerve palsy as the first manifestation of the disease, which is rarely reported in medical literature.


2016 ◽  
Vol 2 ◽  
pp. 205951311664212
Author(s):  
Stratos S Sofos ◽  
J Ewing ◽  
LC Hughes ◽  
MI James

[Formula: see text] Toxic epidermal necrolysis (TEN) is a rare, acute life-threatening mucocutaneous disorder that is characterised by epidermal loss/exfoliation exceeding 30% total body surface area (TBSA) and is on a spectrum that includes erythema multiforme and Stevens–Johnson syndrome (SJS). It is estimated that 80% of TEN cases are related to medication reactions; the association based on the recognition that TEN usually develops 1–3 weeks following administration of the suspect drug. It is agreed that primary treatment consists of prompt withdrawal of causative drugs and transfer to a regional burn unit. Transfer to a burn unit, no more than 7 days after onset of symptoms, has been acknowledged as reducing the risk of infections, hospital length of stay and infection-related mortality. Due to the uncertainty surrounding TEN pathogenesis, several different modalities have been proposed for the treatment of TEN, including high-dose intravenous immunoglobulins, plasmapheresis, cyclophosphamide, cyclosporine and systemic steroids; however, these therapies are relatively ineffective. The use of systemic corticosteroids for treatment of TEN has in particular been deemed controversial due to associations with increased infections leading to greater length of hospital stay and increased mortality. Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare relapsing-remitting disorder of unknown aetiology, characterised by granulomatosis inflammation and necrotising vasculitis predominantly affecting small- to medium-sized vessels. While a 5-year survival rate of 75–83% is now realised, relapse and associated morbidity is of concern. The established treatment for GPA follows the recommendations of the French National Authority for Health (HAS) for systematic necrotising vasculitis. With induction treatment, it is recommended that GPA be treated with a combination of systemic corticosteroids and immunosuppressants. A review of the literature failed to identify any previous case where both of these conditions coincide. Our search was conducted through databases which included MEDLINE, PubMed, Scopus, AMED, CINAHL and EMBASE, using keywords: toxic epidermal necrolysis, Wegener’s granulomatosis, granulomatosis with polyangiitis. We submit the rare case of a 22-year-old woman who presented to our regional burn unit with both GPA and TEN, and we discuss the presentation, investigation and multidisciplinary management of the patient, as well as reviewing the literature regarding these two conditions.


2020 ◽  
Vol 16 ◽  
Author(s):  
Samira Alesaeidi ◽  
Seyedeh Yasaman Hashemi-Amir ◽  
Seyed Mohammad Piri ◽  
Soheil Tavakolpour

: Dear Editor, Granulomatosis with polyangiitis (GPA) previously known as Wegener’s Granulomatosis is an anti-neutrophilic cytoplasmic autoantibody (ANCA) associated vasculitis (AAV), usually initially presents with respiratory, renal, and/or ear, nose & throat (ENT) involvement [1]. Recently, rituximab (RTX) is increasingly used for either induction or maintenance phases in GPA [2, 3]. During the GPA, various organs could be involved. However, pancreas involvement in GPA is rarely reported. Until now, there are few reported cases with either a pancreas mass or acute pancreatitis, which in most cases were the first presentation of disease [4-6]. Here we report a complicated ANCA negative GPA patient with both pancreas mass and acute pancreatitis presentation, who had been expired weeks after RTX due sepsis occurrence. A 38-year-old woman with complaining from swelling, pain, and nasal congestion and discharge admitted to Amir-Alam otolaryngology tertiary referral center, Tehran University of Medical Sciences in February 2019. Taking biopsy had confirmed Wegener’s granulomatosis. At the time of admission, assessment severity through the Birmingham Vasculitis Activity Score (BVAS) reveled score of 24, and the patient fell into a major relapse. Prednisolone at the dose of 1 mg/kg/day and one cycle of cyclophosphamide at the dose of 1000 mg were initiated. While she showed drug reaction to cyclophosphamide. Ten days later, the patient started to have epigastric pain, nausea, vomiting, icter and had a progressive rise in liver function tests and bilirubin. Alkaline phosphatase and total bilirubin levels reached at the peak up 1900 unit/liter and 16 mg/dl, respectively. In abdominal CT scan and magnetic resonance cholangiography (MRCP), a mass in pancreas head with the diameter of 26*23 mm in the posterior part of the pancreatic head dilated common bile duct with a diameter of 14mm has been recorded. Accordingly, an endosonography (EUS) was done, showing a pancreas mass in pancreas head. Fine needle biopsy (FNA) pathology showed pancreatitis pattern with no malignant cell. Then an ERCP (endoscopic retrograde cholangio pancreatography) was done and a stent was placed in pancreatic duct along with initiation of prednisolone at the dose of 1 mg/kg/day. After 20 days, the patient’s symptoms resolved, pancreatic mass became smaller, and LFTs became normal. RTX at the dose of 1000 gr has been initiated and the patient discharged with 60 mg/day prednisolone. Two weeks later, she received the second dose of RTX at the dose of 1000 gr. One month after the last dose of RTX, sepsis had occurred and she expired a few days later. In most of the previously reported cases, pancreas involvement was reported as the first presentation of the disease, while in our case was not. Indeed, she first was presented with nasal and respiratory involvement and 1 year later pancreatitis symptoms appeared. In our cases, although RTX and high dose corticosteroids resolved issue, they led in a serious lethal infection. Taken together, both acute pancreatitis and non-malignant pancreatic mass could be presented as the secondary presentations in GPA patients. Although such conditions could be well-managed with high dose glucocorticoids and probably RTX, risk of serious and lethal infections is warned.


2010 ◽  
Vol 10 ◽  
pp. 1078-1083 ◽  
Author(s):  
Aleksandra Gmurczyk ◽  
Shubhada N. Ahya ◽  
Robert Goldschmidt ◽  
George Kim ◽  
L. Tammy Ho ◽  
...  

Wegener's granulomatosis (WG) is a systemic, necrotizing, granulomatous vasculitis of unknown etiology. Approximately 75% of cases present as classic WG with both pulmonary and renal involvement, while the remaining 25% of patients present with a limited form with either predominantly upper or lower respiratory tract symptoms. Ninety percent of WG patients have circulating anti–neutrophil cytoplasmic antibodies (ANCA), and approximately 10% have both circulating ANCA antibodies and concomitant anti–glomerular basement membrane (anti-GBM) disease on renal biopsy. Virtually all of these patients also have circulating anti-GBM antibodies. While it has been reported that some patients with ANCA vasculitis have circulating anti-GBM antibodies, and patients with anti-GBM disease may have positive ANCA, review of the literature does not demonstrate other cases of biopsy-proven, simultaneous, ANCA-associated vasculitis and anti-GBM disease. We report a case of simultaneous, biopsy-proven, classic, ANCA-positive WG and anti-GBM disease, but without detectible circulating anti-GBM antibodies. We present findings characteristic of both WG and linear IgG deposition along the GBM suggesting concurrent anti-GBM disease, in the absence of detectable circulating anti-GBM antibodies. Possible theories to explain the absence of these antibodies are discussed.


2014 ◽  
Vol 128 (9) ◽  
pp. 831-837 ◽  
Author(s):  
N P Jordan ◽  
H Verma ◽  
A Siddiqui ◽  
G A Morrison ◽  
D P D'Cruz

AbstractObjectives:We aimed to determine the prevalence of symptomatic subglottic laryngotracheal stenosis in patients with granulomatosis with polyangiitis (Wegener's granulomatosis); we also wanted to characterise the clinical outcomes and surgical interventions required, and the relapse rate in our cohort.Methods:We undertook a retrospective clinical review of all granulomatosis with polyangiitis patients with symptomatic subglottic laryngotracheal stenosis attending St Thomas' Hospital, London, United Kingdom.Results:Symptomatic subglottic laryngotracheal stenosis developed in 16 per cent of granulomatosis with polyangiitis patients attending our clinic. The median age of patients at diagnosis was 44 years (range: 34–81 years); 78 per cent of those presenting with subglottic laryngotracheal stenosis were women and 22 per cent were men. All patients were white; 67 per cent of patients were proteinase 3-antineutrophil cytoplasmic antibody-positive and 67 per cent developed relapsing disease requiring repeated surgical intervention. Subglottic laryngotracheal stenosis relapse was not associated with active systemic vasculitis elsewhere.Conclusion:Subglottic laryngotracheal stenosis is an uncommon but significant complication of granulomatosis with polyangiitis. Management of subglottic laryngotracheal stenosis requires a multi-disciplinary approach, with both rheumatological and otolaryngological expertise involved, given the relapsing nature of the disease.


2020 ◽  
Vol 31 (2) ◽  
pp. 114-119
Author(s):  
Wafia Najifa ◽  
Mohiuddin Sharif ◽  
Rajib Roy ◽  
Mahfuzul Haque ◽  
Md Robed Amin

The presentation of Rheumatoid arthritis (RA) combined with a second rheumatological disorder thatis, different RA overlap syndromes are frequently encountered in clinical practice. But RA-vasculitisoverlaps are relatively rare. This paper presents a case of Rheumatoid arthritis and Granulomatosiswith polyangiitis (Wegener granulomatosis) overlap syndrome which is first of its kind reported from Bangladesh. Bangladesh J Medicine July 2020; 31(2) : 114-119


Sign in / Sign up

Export Citation Format

Share Document